Cyclo3pss Corporation (CYPS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cyclo3pss Corporation (CYPS) trades at $0.00 with AI Score 53/100 (Grade B). Cyclo3pss Corporation, founded in 1927, historically specialized in ozone food processing products, commercial laundry systems, and R&D for sterilization technologies. Market cap: $4,054, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CYPS: CYPS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYPS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CYPS: the 6 perspectives are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Cyclo3pss Corporation (CYPS) Healthcare & Pipeline Overview
Cyclo3pss Corporation, founded in 1927, historically specialized in ozone food processing products, commercial laundry systems, and R&D for sterilization technologies. Based in Salt Lake City, Utah, the company suspended all operations in July 2002 due to an inability to secure necessary financing, marking its current dormant status within the Healthcare sector.
What Is the Investment Thesis for CYPS?
The investment thesis for Cyclo3pss Corporation (CYPS) is fundamentally shaped by its current operational status. The company, which historically engaged in ozone food processing products, commercial laundry systems, and sterilization R&D, formally suspended all operations in July 2002. This suspension was a direct consequence of an inability to secure necessary financing and attract willing investors. As of the current date, there is no indication from the provided data that operations have resumed or are planned to resume. Financially, CYPS exhibits a market capitalization of 4K and a free cash flow of $-0.00 billion, reflecting its dormant state. The reported profit margin of -232.3% and a gross margin of 36.6% are historical metrics that predate or immediately followed the operational suspension, highlighting significant financial challenges. With a beta of 21.99, the stock historically demonstrated extreme volatility, though this metric's relevance is diminished given the lack of active trading and operations. Value drivers are currently non-existent, as the company generates no revenue and has no active business. Any potential for future value would hinge entirely on an unforeseen and unannounced revival of operations, which is not supported by current information.
Based on FMP financials and quantitative analysis
CYPS Key Highlights
- Market Capitalization: Reported at $0.00 billion, reflecting the company's dormant status and minimal market valuation.
- Profit Margin: A historical profit margin of -232.3% indicates significant unprofitability during its operational period or immediately prior to suspension.
- Gross Margin: A gross margin of 36.6% suggests that while the company could generate revenue above direct costs, operational expenses significantly outweighed this.
- Free Cash Flow: Recorded at $-0.00 billion, consistent with a company that has suspended all operations and is not generating cash.
- Operational Status: All company operations were suspended in July 2002 due to an inability to secure necessary financing, rendering it currently inactive.
Who Are CYPS's Competitors?
CYPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| AKU Akumin Inc. | $0.29 | -17.87% | $26.27M | 53 |
| CLIFF Cordlife Group Limited | $0.15 | +0.00% | $38.57M | 53 |
| CEMI Chembio Diagnostics, Inc. | $0.46 | +0.22% | $16.71M | 53 |
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127.35M | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYPS's Key Strengths?
- Historical expertise in ozone-based sterilization and processing technologies.
- Established R&D capabilities in consumer product disinfection.
- Long operating history since 1927, indicating foundational knowledge.
- Specialized product offerings for niche industrial applications.
What Are CYPS's Weaknesses?
- Suspended all operations in July 2002 due to financial insolvency.
- Inability to secure necessary and suitable financing.
- Extremely negative profit margin (-232.3%) historically.
- Minimal employee base (4 employees) indicating limited operational capacity.
What Could Drive CYPS Stock Higher?
- The company suspended all operations in July 2002 due to an inability to secure necessary financing, indicating no active business catalysts.
- No upcoming operational catalysts are identified as the company remains dormant. Any future catalysts would depend on a successful capital raise and a decision to resume business activities, which is not indicated by the provided data.
What Are the Key Risks for CYPS?
- All company operations have been suspended since July 2002, leading to no active revenue generation or business activities.
- Persistent inability to secure necessary and suitable financing, which was the stated reason for operational suspension.
- Extreme historical unprofitability, evidenced by a profit margin of -232.3%, suggesting significant challenges if operations were to resume.
- Very high historical beta of 21.99, indicating extreme price volatility and speculative nature if the stock were actively traded.
- Lack of public disclosure and transparency ("Unknown" disclosure status) poses significant information risk for investors.
What Are the Growth Opportunities for CYPS?
- Reactivation of Ozone Food Processing Division: If Cyclo3pss Corporation were to reactivate its operations, a potential growth opportunity would lie in re-entering the ozone food processing market. This market, driven by increasing consumer demand for natural preservation methods and stringent food safety regulations, could offer a pathway for renewed revenue. The global food processing equipment market was valued at over $100 billion in recent years, with sterilization and preservation technologies forming a significant component. Re-establishing its licensing, manufacturing, and sales channels for these products, potentially with updated technology, would require substantial capital investment and strategic partnerships. However, based on the provided data, the company suspended all operations in July 2002 and has not indicated any plans for reactivation, rendering this a purely hypothetical opportunity.
- Modernization of Commercial Laundry Systems: Another hypothetical growth avenue, should the company resume operations, would involve modernizing and re-introducing its ozone washing and laundry sorting and counting systems. The commercial and institutional laundry market continues to evolve, with a growing emphasis on energy efficiency, water conservation, and advanced automation. A revitalized Cyclo3pss could develop next-generation ozone systems that offer superior performance, reduced environmental impact, and enhanced data analytics for operational efficiency. This would target a market that seeks innovative solutions to lower operating costs and improve hygiene standards. However, as the company suspended all operations in July 2002 due to an inability to secure financing, this opportunity is not currently applicable.
- Expansion of Sterilization R&D into New Applications: Historically, Cyclo3pss engaged in research and development for the sterilization and disinfection of certain consumer products. If operations were to resume, a significant growth opportunity could involve leveraging this R&D expertise to develop new applications for ozone technology beyond its traditional food and laundry sectors. This could include medical device sterilization, air and water purification systems, or even household disinfection products, tapping into broader public health and environmental markets. The global disinfection and sterilization market is projected to reach tens of billions of dollars. However, given the company's operational suspension since July 2002 due to financial constraints, there are no ongoing R&D activities or identified pathways for such expansion.
- Strategic Partnerships for Technology Licensing: In a hypothetical scenario where Cyclo3pss reactivates, its historical intellectual property in ozone technology could be a valuable asset for strategic partnerships. Licensing its proprietary ozone food processing or laundry system technologies to larger, established manufacturers or distributors could provide a low-capital entry point back into the market. Such partnerships could accelerate market penetration and generate royalty income without requiring extensive direct operational investment. This strategy would capitalize on its historical R&D and product development. However, as the company suspended all operations in July 2002 due to an inability to locate willing investors and secure financing, this remains a theoretical opportunity without current applicability.
- Targeting Emerging Markets for Sanitation Solutions: If Cyclo3pss were to resume operations, a potential growth opportunity could involve targeting emerging markets that are increasingly investing in modern sanitation infrastructure and food safety standards. These markets often present less saturated competitive landscapes and a high demand for cost-effective, efficient disinfection and processing technologies. Adapting its ozone systems to meet the specific needs and regulatory environments of these regions could open new revenue streams. However, the company's operations have been suspended since July 2002 due to a lack of financing, and there is no indication of active business development or market expansion initiatives. Therefore, this opportunity is purely speculative in the current context.
What Opportunities Does CYPS Have?
- Potential (hypothetical) for a future revival if new investors and financing are secured.
- Growing market demand for advanced sterilization and food safety technologies.
- Potential to license historical intellectual property if operations were to resume.
- Re-entry into commercial laundry systems with updated, energy-efficient ozone technology.
What Threats Does CYPS Face?
- Continued operational dormancy leading to irrelevance and potential delisting.
- Technological obsolescence of historical products and R&D if not updated.
- Intense competition from active companies in the sterilization and industrial sanitation markets.
- Inability to attract capital for any potential future restart of operations.
What Are CYPS's Competitive Advantages?
- Historical specialization in ozone-based technologies for specific industrial applications.
- Proprietary knowledge and intellectual property developed through its R&D efforts in ozone sterilization.
- Early market presence in ozone food processing and commercial laundry systems since its founding in 1927.
- Established expertise in the licensing, manufacturing, and installation of complex ozone systems.
- However, the company's operational suspension since 2002 significantly diminishes the current relevance of these historical competitive advantages.
What Does CYPS Do?
Cyclo3pss Corporation, established in 1927 and headquartered in Salt Lake City, Utah, historically operated within the Healthcare sector, specifically focusing on Medical - Diagnostics & Research. The company's primary business activities encompassed the licensing, manufacturing, sale, and installation of specialized ozone food processing products. These systems were designed to enhance food safety and preservation through advanced ozone application technologies. Beyond the food industry, Cyclo3pss also developed and marketed ozone washing and laundry sorting and counting systems tailored for commercial and institutional laundries, addressing efficiency and sanitation needs in large-scale operations. In addition to its product lines, Cyclo3pss maintained a research and development arm dedicated to exploring and advancing technologies for the sterilization and disinfection of various consumer products. This R&D focus aimed to innovate solutions for public health and hygiene, aligning with its broader mission within the healthcare domain. For decades, the company contributed to specialized industrial and commercial sanitation markets with its unique ozone-based offerings. However, a pivotal moment occurred in July 2002 when the Board of Directors made the decision to immediately suspend all company operations. This drastic measure was necessitated by a critical inability to locate willing investors and secure the essential and suitable financing required to sustain its business activities. Consequently, Cyclo3pss Corporation has remained dormant since that time, with its historical operations ceased and no active business functions reported. Its legacy remains in its past contributions to ozone technology applications in food and laundry sectors, alongside its prior R&D endeavors.
What Products and Services Does CYPS Offer?
- Licenses, manufactures, sells, and installs ozone food processing products.
- Provides ozone washing and laundry sorting and counting systems for commercial and institutional laundries.
- Engages in research and development of technologies for sterilizing and disinfecting consumer products.
- Historically focused on advanced ozone application technologies for sanitation and preservation.
- Aimed to serve the food industry and large-scale commercial laundry operations.
- Conducted R&D to innovate solutions for public health and hygiene.
- Suspended all operations in July 2002 due to financial difficulties.
How Does CYPS Make Money?
- Historically generated revenue through the sale and installation of ozone-based processing and laundry systems.
- Engaged in licensing its proprietary ozone technology to other entities.
- Invested in research and development, aiming to commercialize new sterilization and disinfection technologies.
- Focused on B2B sales to commercial and institutional clients in food and laundry sectors.
- Operations have been suspended since July 2002, indicating no active revenue generation.
What Industry Does CYPS Operate In?
Cyclo3pss Corporation historically positioned itself within the specialized segments of the Healthcare sector, specifically under Medical - Diagnostics & Research, by focusing on ozone-based technologies. Its business model addressed critical needs in food safety and commercial sanitation. The market for ozone food processing, while niche, targets the broader food industry's demand for effective, chemical-free sterilization and preservation methods. Similarly, ozone washing and laundry systems cater to the commercial and institutional laundry sector, which continuously seeks efficient, environmentally friendly, and cost-effective solutions for high-volume sanitation. The company's R&D efforts in consumer product sterilization also aligned with public health trends. Historically, the competitive landscape would have included other providers of industrial sterilization equipment and commercial laundry solutions, as well as companies developing alternative disinfection technologies. However, with operations suspended since July 2002, Cyclo3pss is no longer an active participant in these markets, and its historical positioning is now a matter of record rather than current market influence.
Who Are CYPS's Key Customers?
- Commercial food processing facilities requiring sterilization and preservation solutions.
- Institutional laundries, such as hospitals, hotels, and large commercial cleaning services.
- Potentially, consumers indirectly through R&D for consumer product sterilization (if commercialized).
- Historically, businesses seeking advanced ozone technology for sanitation and efficiency.
- Currently, no active customer base due to suspended operations.
ROE 0%Key Financial Metrics
Return on equity for Cyclo3pss Corporation stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. CYPS trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Cyclo3pss Corporation (CYPS) Valuation Context
Valued at 4K, CYPS is classified as a micro-cap stock. Relative to its peer group, CYPS's quantitative score of 53/100 is below the peer average of 64/100.
Company Profile
Cyclo3pss Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO William R. Stoddard. CYPS has traded publicly since 2010.
CYPS Financials
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, suggesting confidence from leadership in the company's future prospects.
- Positive community sentiment has emerged as discussions around product innovations gain traction, reflecting optimism among investors.
- Recent partnerships have been announced, enhancing the company's market position and potential revenue streams.
- The overall market perception has shifted favorably, with analysts recognizing the company's strategic initiatives as promising.
Bear Case
- Concerns about market competition have intensified, with some community members voicing skepticism about Cyclo3pss's ability to maintain its edge.
- Recent earnings reports have raised questions regarding operational efficiency, leading to some bearish sentiment in trading forums.
- There is a growing perception that the stock may be overvalued based on its current fundamentals, leading to cautious views among investors.
- Market volatility has led to increased uncertainty, with some traders expressing doubts about the company's short-term stability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CYPS Latest News
No recent news available for CYPS.
CYPS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYPS.
Price Targets
Wall Street price target analysis for CYPS.
CYPS MoonshotScore
What does this score mean?
The MoonshotScore rates CYPS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William R. Stoddard
CEO
William R. Stoddard serves as the CEO of Cyclo3pss Corporation. Details regarding his specific educational background, prior executive roles, or comprehensive career history are not provided in the available data. His leadership is noted in the context of managing the company's small team of four employees. Given the company's operational status, his role has primarily been associated with the oversight of a dormant entity rather than active business development or expansion. The limited information suggests a focus on administrative aspects during a period of non-operation for Cyclo3pss Corporation.
Track Record: Under William R. Stoddard's leadership, Cyclo3pss Corporation's Board of Directors made the decision in July 2002 to suspend all company operations. This critical strategic decision was a direct response to the company's inability to locate willing investors and secure necessary and suitable financing. His tenure has therefore been characterized by the management of a company in a state of operational dormancy. No specific achievements related to business growth, product launches, or market expansion are available in the provided data.
CYPS OTC Market Information
Cyclo3pss Corporation trades on the OTC market under the "OTC Other" tier. This designation typically applies to companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the stringent requirements of major exchanges like the NYSE or NASDAQ. Companies in the "OTC Other" tier often have limited public information, may not file with the SEC, and can be considered speculative. Unlike exchanges with strict listing standards for market capitalization, financial health, and governance, "OTC Other" has minimal requirements, resulting in a wide range of company quality and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of public disclosure and financial transparency due to "Unknown" disclosure status.
- Extremely low liquidity and potential for no active trading, making exiting positions difficult.
- Company operations suspended since 2002, indicating no active business or revenue generation.
- High historical beta (21.99) suggests extreme price volatility if trading were to resume.
- Risk of delisting or further market tier degradation due to prolonged dormancy and lack of reporting.
- Verify the current operational status and any potential plans for reactivation (not indicated in data).
- Attempt to locate any available financial statements or disclosures, despite "Unknown" status.
- Research the background and current involvement of management, particularly William R. Stoddard.
- Assess the legal and regulatory standing of the company, including any outstanding obligations.
- Investigate historical assets or intellectual property that might hold residual value.
- Examine any recent trading activity or market maker interest, if discernible.
- Understand the implications of the 4K market cap and negative financial metrics.
- Founded in 1927, indicating a long historical corporate existence.
- Clearly defined historical business activities in ozone food processing and laundry systems.
- Headquartered in Salt Lake City, Utah, providing a verifiable physical location.
- Identified CEO/Leadership (William R. Stoddard) with a stated role.
- However, the suspension of operations since 2002 and "Unknown" disclosure status significantly diminish current operational legitimacy.
What Investors Ask About Cyclo3pss Corporation (CYPS) — Healthcare
What does Cyclo3pss Corporation do, and what was its historical market focus?
Cyclo3pss Corporation, founded in 1927, historically specialized in the licensing, manufacture, sale, and installation of ozone food processing products. These systems were designed for sterilization and preservation within the food industry. Additionally, the company provided ozone washing and laundry sorting and counting systems for commercial and institutional laundries, addressing sanitation and efficiency needs in large-scale operations. It also conducted research and development into technologies for the sterilization and disinfection of various consumer products. Its market focus was primarily B2B, serving industries that required advanced ozone-based solutions for hygiene and processing. However, all operations were suspended in July 2002 due to financial constraints.
What are the main risks associated with investing in CYPS, particularly given its operational status?
The primary risks associated with Cyclo3pss Corporation stem from its operational dormancy. The company suspended all operations in July 2002 due to an inability to secure financing, meaning it currently generates no revenue and has no active business. This leads to extremely low, if any, liquidity for its stock, making it difficult to buy or sell shares. The "Unknown" disclosure status means there is no public financial reporting, creating significant information asymmetry. Furthermore, its historical profit margin of -232.3% indicates severe unprofitability, and a beta of 21.99 suggests extreme volatility if trading were active. These factors collectively present substantial investment risk.
What is the current operational status of Cyclo3pss Corporation, and what led to this situation?
Cyclo3pss Corporation's current operational status is dormant. In July 2002, the company's Board of Directors made the decision to immediately suspend all operations. This critical decision was driven by a fundamental inability to locate willing investors and secure the necessary and suitable financing required to sustain its business activities. As of today, 2026-06-14, there is no indication from the provided data that operations have resumed or that any plans for reactivation are underway. Consequently, the company is not actively engaged in its historical business of ozone food processing, laundry systems, or R&D.
What are the key factors to evaluate for CYPS?
Cyclo3pss Corporation (CYPS) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does CYPS data refresh on this page?
CYPS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CYPS's recent stock price performance?
Cyclo3pss Corporation (CYPS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Historical expertise in ozone-based sterilization and processing technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYPS overvalued or undervalued right now?
Valuing Cyclo3pss Corporation (CYPS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CYPS?
Before investing in Cyclo3pss Corporation (CYPS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided data.
- Company operations suspended in July 2002, impacting applicability of certain forward-looking analysis sections.
- Lack of detailed financial history beyond provided metrics.
- No FMP PEER TICKERS were provided, so competitor list is empty.